Kura Oncology, Inc. (NASDAQ:KURA) Receives $28.00 Average Price Target from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have received a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $27.7143.

Several equities research analysts recently issued reports on KURA shares. UBS Group raised their target price on shares of Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Barclays reissued an “overweight” rating and set a $28.00 price target (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Finally, Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI early commercial traction — management reported $2.1M in net product revenue from ~5 weeks of sales and rapid payer coverage (~80% of private payers aligned to label), supporting near-term uptake expectations. Q4 & Corporate Update
• Positive Sentiment: Material milestone payments & cash runway — Kura recorded collaboration revenue and milestone receipts (including a reported $135M channel milestone and additional $30M payments tied to Phase 3 dosing) and ended 2025 with $667.2M cash plus ~$180M anticipated collaboration payments, which management says funds operations into pivotal Phase 3 topline results. This reduces near‑term financing risk. Q4 Financials
• Neutral Sentiment: Pipeline cadence: management flagged multiple 2026 data readouts and enrollment progress (pivotal KOMET‑017 frontline trials, KOMET‑007 combos, FIT‑001 expansion). These are potential future catalysts but carry binary clinical risk. Corporate Update
• Neutral Sentiment: Inducement grants: the company issued options for 44,700 shares to four new hires under Nasdaq rules — modest potential dilution and a routine hiring incentive. Inducement Grants
• Negative Sentiment: Q4 earnings and revenue miss — Kura reported a $0.92 loss per share vs. consensus -$0.72 and Q4 revenue of $17.3M vs. est. ~$34.7M. R&D and SG&A rose sharply, driving a wider net loss ($81M). These miss metrics explain selling pressure despite commercial progress. Earnings Recap
• Negative Sentiment: Safety profile and boxed warning remain material risks — differentiation syndrome, QTc prolongation and other serious AEs were highlighted in the label and trial experience; these safety issues can limit uptake, dosing, and label expansion. Safety & Label
• Negative Sentiment: Analyst note: Wedbush trimmed its price target from $38 to $36 (rating remains Outperform), a modest downgrade that may temper upside sentiment despite bullish coverage from other firms. Analyst Update

Kura Oncology Stock Performance

KURA traded up $0.45 during midday trading on Friday, hitting $8.96. 1,988,247 shares of the company traded hands, compared to its average volume of 1,508,871. The company’s 50-day moving average is $8.75 and its 200 day moving average is $9.39. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $779.70 million, a PE ratio of -2.82 and a beta of 0.22. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $12.49.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative return on equity of 91.62% and a negative net margin of 412.95%.The company had revenue of $17.34 million during the quarter, compared to the consensus estimate of $34.71 million. On average, research analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Insider Buying and Selling at Kura Oncology

In other news, insider Francis Burrows sold 23,726 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $9.78, for a total transaction of $232,040.28. Following the completion of the sale, the insider owned 33,735 shares of the company’s stock, valued at $329,928.30. This represents a 41.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Thomas James Doyle sold 7,142 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $60,421.32. Following the completion of the transaction, the senior vice president owned 145,167 shares in the company, valued at $1,228,112.82. This trade represents a 4.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 59,794 shares of company stock worth $537,176. 6.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc boosted its stake in shares of Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after acquiring an additional 1,284 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares in the last quarter. Allworth Financial LP raised its holdings in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares during the period. PNC Financial Services Group Inc. raised its holdings in Kura Oncology by 127.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after purchasing an additional 3,769 shares during the period. Finally, Merit Financial Group LLC purchased a new position in Kura Oncology during the third quarter valued at $89,000.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.